Molecular Biology Pharma Companies Small Molecule 
Drug Target Review
APRIL 19, 2024
Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. And so, I have been the managerial co-founder and CEO of Sibylla since 2017. This multidisciplinary approach is at the heart of Sibylla.
Elrig
APRIL 29, 2024
Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader. There, I supported AI-enabled DD efforts in their small molecule portfolio. big pharma or startups/spin off? Bioinformatics is all about bringing together different areas of knowledge.
Expert insights. Personalized for you.
111 
Let's personalize your content